FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156684512> ?p ?o ?g. }

• W2156684512 abstract "Abstract Background/aims Breast cancer metastasis suppressor 1 (BRMS1) blocks metastasis in melanoma xenografts; however, its usefulness as a biomarker in human melanomas has not been widely studied. The goal was to measure BRMS1 expression in benign nevi, primary and metastatic melanomas and evaluate its impact on disease progression and prognosis. Methods Paraffin-embedded tissue from 155 primary melanomas, 69 metastases and 15 nevi was examined for BRMS1 expression using immunohistochemistry. siRNA mediated BRMS1 down-regulation was used to study impact on invasion and migration in melanoma cell lines. Results A significantly higher percentage of nevi (87%), compared to primary melanomas (20%) and metastases (48%), expressed BRMS1 in the nucelus (p < 0.0001). Strong nuclear staining intensity was observed in 67% of nevi, and in 9% and 24% of the primary and metastatic melanomas, respectively (p < 0.0001). Comparable cytoplasmic expression was observed (nevi; 87%, primaries; 86%, metastases; 72%). However, a decline in cytoplasmic staining intensity was observed in metastases compared to nevi and primary tumors (26%, 47%, and 58%, respectively, p < 0.0001). Score index (percentage immunopositive celles multiplied with staining intensity) revealed that high cytoplasmic score index (≥ 4) was associated with thinner tumors (p = 0.04), lack of ulceration (p = 0.02) and increased disease-free survival (p = 0.036). When intensity and percentage BRMS1 positive cells were analyzed separately, intensity remained associated with tumor thickness (p = 0.024) and ulceration (p = 0.004) but was inversely associated with expression of proliferation markers (cyclin D3 (p = 0.008), cyclin A (p = 0.007), and p21 Waf1/Cip1 (p = 0.009)). Cytoplasmic score index was inversely associated with nuclear p-Akt (p = 0.013) and positively associated with cytoplasmic p-ERK1/2 expression (p = 0.033). Nuclear BRMS1 expression in ≥ 10% of primary melanoma cells was associated with thicker tumors (p = 0.016) and decreased relapse-free period (p = 0.043). Nuclear BRMS1 was associated with expression of fatty acid binding protein 7 (FABP7; p = 0.011), a marker of invasion in melanomas. In line with this, repression of BRMS1 expression reduced the ability of melanoma cells to migrate and invade in vitro . Conclusion Our data suggest that BRMS1 is localized in cytoplasm and nucleus of melanocytic cells and that cellular localization determines its in vivo effect. We hypothesize that cytoplasmic BRMS1 restricts melanoma progression while nuclear BRMS1 possibly promotes melanoma cell invasion. Please see related article: http://www.biomedcentral.com/1741-7015/10/19" @default.
• W2156684512 created "2016-06-24" @default.
• W2156684512 creator A5041567552 @default.
• W2156684512 creator A5043285000 @default.
• W2156684512 creator A5049850477 @default.
• W2156684512 creator A5050991817 @default.
• W2156684512 creator A5053950619 @default.
• W2156684512 creator A5056217370 @default.
• W2156684512 creator A5076168843 @default.
• W2156684512 date "2012-02-22" @default.
• W2156684512 modified "2023-09-27" @default.
• W2156684512 title "Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival" @default.
• W2156684512 cites W1492304029 @default.
• W2156684512 cites W1967739793 @default.
• W2156684512 cites W1972962871 @default.
• W2156684512 cites W1981985776 @default.
• W2156684512 cites W1998924500 @default.
• W2156684512 cites W2003729329 @default.
• W2156684512 cites W2008963451 @default.
• W2156684512 cites W2009346965 @default.
• W2156684512 cites W2019579079 @default.
• W2156684512 cites W2024073746 @default.
• W2156684512 cites W2031829676 @default.
• W2156684512 cites W2033919910 @default.
• W2156684512 cites W2035844507 @default.
• W2156684512 cites W2036362283 @default.
• W2156684512 cites W2037986858 @default.
• W2156684512 cites W2064462464 @default.
• W2156684512 cites W2065289052 @default.
• W2156684512 cites W2067882412 @default.
• W2156684512 cites W2081236313 @default.
• W2156684512 cites W2081502960 @default.
• W2156684512 cites W2093833764 @default.
• W2156684512 cites W2118936905 @default.
• W2156684512 cites W2120165607 @default.
• W2156684512 cites W2123287557 @default.
• W2156684512 cites W2124133814 @default.
• W2156684512 cites W2128416360 @default.
• W2156684512 cites W2139146830 @default.
• W2156684512 cites W2161080185 @default.
• W2156684512 cites W2163750921 @default.
• W2156684512 cites W4244068819 @default.
• W2156684512 doi "https://doi.org/10.1186/1471-2407-12-73" @default.
• W2156684512 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3341185" @default.
• W2156684512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22356677" @default.
• W2156684512 hasPublicationYear "2012" @default.
• W2156684512 type Work @default.
• W2156684512 sameAs 2156684512 @default.
• W2156684512 citedByCount "27" @default.
• W2156684512 countsByYear W21566845122012 @default.
• W2156684512 countsByYear W21566845122013 @default.
• W2156684512 countsByYear W21566845122014 @default.
• W2156684512 countsByYear W21566845122015 @default.
• W2156684512 countsByYear W21566845122016 @default.
• W2156684512 countsByYear W21566845122017 @default.
• W2156684512 countsByYear W21566845122018 @default.
• W2156684512 countsByYear W21566845122019 @default.
• W2156684512 countsByYear W21566845122020 @default.
• W2156684512 countsByYear W21566845122022 @default.
• W2156684512 countsByYear W21566845122023 @default.
• W2156684512 crossrefType "journal-article" @default.
• W2156684512 hasAuthorship W2156684512A5041567552 @default.
• W2156684512 hasAuthorship W2156684512A5043285000 @default.
• W2156684512 hasAuthorship W2156684512A5049850477 @default.
• W2156684512 hasAuthorship W2156684512A5050991817 @default.
• W2156684512 hasAuthorship W2156684512A5053950619 @default.
• W2156684512 hasAuthorship W2156684512A5056217370 @default.
• W2156684512 hasAuthorship W2156684512A5076168843 @default.
• W2156684512 hasBestOaLocation W21566845121 @default.
• W2156684512 hasConcept C121608353 @default.
• W2156684512 hasConcept C126322002 @default.
• W2156684512 hasConcept C142724271 @default.
• W2156684512 hasConcept C143998085 @default.
• W2156684512 hasConcept C199835354 @default.
• W2156684512 hasConcept C204232928 @default.
• W2156684512 hasConcept C2777658100 @default.
• W2156684512 hasConcept C2779013556 @default.
• W2156684512 hasConcept C2780140570 @default.
• W2156684512 hasConcept C2781197716 @default.
• W2156684512 hasConcept C29537977 @default.
• W2156684512 hasConcept C502942594 @default.
• W2156684512 hasConcept C55493867 @default.
• W2156684512 hasConcept C71924100 @default.
• W2156684512 hasConcept C74864618 @default.
• W2156684512 hasConcept C86803240 @default.
• W2156684512 hasConceptScore W2156684512C121608353 @default.
• W2156684512 hasConceptScore W2156684512C126322002 @default.
• W2156684512 hasConceptScore W2156684512C142724271 @default.
• W2156684512 hasConceptScore W2156684512C143998085 @default.
• W2156684512 hasConceptScore W2156684512C199835354 @default.
• W2156684512 hasConceptScore W2156684512C204232928 @default.
• W2156684512 hasConceptScore W2156684512C2777658100 @default.
• W2156684512 hasConceptScore W2156684512C2779013556 @default.
• W2156684512 hasConceptScore W2156684512C2780140570 @default.
• W2156684512 hasConceptScore W2156684512C2781197716 @default.
• W2156684512 hasConceptScore W2156684512C29537977 @default.
• W2156684512 hasConceptScore W2156684512C502942594 @default.
• W2156684512 hasConceptScore W2156684512C55493867 @default.
• W2156684512 hasConceptScore W2156684512C71924100 @default.
• W2156684512 hasConceptScore W2156684512C74864618 @default.

• next